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Hypervariable region 1 (HVR1) proteins of hepatitis C virus (HCV) have been reported to react broadly with sera of patients
with HCV infection. However, the variability of the broad reactivity of individual HVR1 proteins has not been elucidated. We
assessed the reactivity of 25 different HVR1 proteins (genotype 1b) with sera of 81 patients with HCV infection (genotype 1b)
by Western blot. HVR1 proteins reacted with 2–60 sera. The number of sera reactive with each HVR1 protein significantly
correlated with the number of amino acid residues identical to the consensus sequence defined by Puntoriero et al. (G.
Puntoriero, A. Lahm, S. Zucchelli, B. B. Ercole, R. Tafi, M. Penzzanera, M. U. Mondelli, R. Cortese, A. Tramontano, G. Galfre’,
and A. Nicosia. 1998. EMBO J. 17, 3521–3533.) (r 5 0.561, P , 0.005). The most widely reactive HVR1 protein, 12-22, had a
sequence similar to the consensus sequence. The peptide with C-terminal 13-amino-acids sequence of HVR1 protein 12-22
(NH2-CSFTSLFTPGPSQK) was injected into rabbits as an immunogen. The rabbit immune sera reacted with 9 of 25 HVR1
proteins of genotype 1b including HVR1 protein 12-22 and with 3 of 12 proteins of genotype 2a. These results indicate that
the HVR1 protein broadly reactive with patients’ sera has a sequence similar to the consensus sequence, can induce broadly
reactive sera, and could be one of the candidate immunogens in a prophylactic vaccine against HCV. © 1999 Academic Press
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6INTRODUCTION
Hepatitis C virus (HCV) is a single-stranded positive-
ense RNA of ;9.4 kilonucleotides and the major etio-
ogical agent of non-A, non-B hepatitis (Choo et al., 1989;
uo et al., 1989). HCV infection often progresses to
hronic hepatitis, cirrhosis, and hepatocellular carci-
oma (Kiyosawa et al., 1990).
Multiple lines of evidence indicate that one of the
rincipal neutralization determinants corresponds to the
ypervariable region 1 (HVR1) of E2/NS1 region. Hyper-
mmune serum against HVR1 was demonstrated to pre-
ent HCV infection in cell cultures (Shimizu et al., 1996)
nd in chimpanzees (Farci et al., 1996). HVR1 shows
requent mutations and quasispecies nature where virus
ariants with heterogeneous sequences coexist (Hijikata
t al., 1991; Ogata et al., 1991; Weiner et al., 1991; Higashi
t al., 1992; Martell et al., 1992). These variations of HVR1
ave been proposed to be responsible for the persis-
ence of HCV infection through escape from neutralizing
ntibody (Weiner et al., 1992; Kato et al., 1993; Taniguchi
t al., 1993). This would pose a major obstacle to the
evelopment of a vaccine based on HVR1 as the antigen.
Despite its hypervariability, HVR1 has highly con-
1 To whom reprint requests should be addressed. Fax: 052-744-2208.
t-mail: kanken@tsuru.med.nagoya-u.ac.jp.
153erved amino acid sites, and even the variable positions
re occupied by a limited number of amino acids (Sekiya
t al., 1994; Nakamoto et al., 1996; McAllister et al., 1998;
untoriero et al., 1998). Correspondingly, there are anti-
VR1 antibodies cross-reactive with the different HVR1
eptides (da Silva Cardoso et al., 1995; Scarselli et al.,
995; Hattori et al., 1998). In the present investigation, we
tudied the broadness of the reactivity of 25 HVR1 pro-
eins with patients’ sera and assessed its correlation to
he similarity of their sequences to the consensus se-
uence defined by Puntoriero et al. (1998). We also im-
unized rabbits with the peptide bearing the sequence
f the most broadly reactive HVR1 protein, and assessed
he reactivity of rabbit immune sera with various HVR1
roteins.
RESULTS
eactivity of 25 HVR1 proteins with 81 patients’ sera
The reactivity of the 25 HVR1 fusion proteins with the
1 patients’ sera was assessed by Western blot. ODs
0.1 were considered as positive. No reactivity to plain
ST was detected in any of the 81 patients’ sera. Each
VR1 protein reacted with 2–60 patients’ sera (Fig. 1 and
able 1). Fusion protein 12-22 reacted most broadly with
0 patients’ sera. The sera reacted with a variable por-ion of the 25 HVR1 proteins; 2 sera with 21 and 23
0042-6822/99 $30.00
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154 WATANABE ET AL.roteins, respectively, 8 sera with 16–20 proteins, 13 sera
ith 11–15, 20 sera with 6–10, 28 sera reacted with 1–5
roteins, and 10 sera had no detectable anti-HVR1 anti-
odies. The ODs of positive reactivity of HVR1 proteins
ith patients’ sera varied from 0.10 to 3.01. Twenty sera
ad low reactivity with OD of ,1.0 even with the most
eactive HVR1 protein. The reactivity of four sera with
usion protein 12-22 was examined quantitatively by lim-
ting dilutions. Sera were serially diluted fourfold from
:40 dilution. Two sera with ODs of 2.34 and 2.31 were
ositive by 1:2560 dilution. One serum with OD of 1.55
as positive by 1:640 dilution, and one with OD of 0.81
as positive by 1:160 dilution.
The reactivity of the most broadly reactive protein,
2-22, with sera of 30 patients infected by genotype 2a
as assessed. 16 sera (53.3%) were reactive with fusion
rotein 12-22.
orrelation between the broad reactivity of individual
VR1 proteins with patients’ sera and their similarity
o the consensus sequence
Puntoriero et al. reported the consensus sequence
ased on the analysis of 234 published HVR1 sequences
Puntoriero et al., 1998) (Fig. 1). The sequences of the 25
VR1 proteins were compared with the consensus se-
uence, and the relationship between the broadness of
eactivity with patients’ sera and the degree of similarity
o the consensus sequence was assessed. The consen-
us HVR1 sequence defined by Puntoriero et al. was
omposed of 1 to 7 amino acids for each amino acid
osition. When the amino acid in one position of HVR1
roteins was the same with one of the amino acids
efined as the consensus at the same position, we
onsidered the amino acid as identical to the consensus
equence (Fig. 1 and Table 1). When all of the 27 amino
cids of HVR1 were studied, the number of amino acid
esidues identical to the consensus sequence signifi-
antly correlated with the number of sera reactive with
ach HVR1 protein (r 5 0.561, P , 0.005) (Fig. 2). When
he C-terminal 13 amino acids were assessed, the num-
er of amino acids identical to the consensus sequence
lso significantly correlated with the number of sera
eactive with each HVR1 protein (r 5 0.474, P , 0.05).
eactivity of immunized rabbits’ sera with HVR1
roteins
The sera of rabbits immunized with C-terminal 13-
mino-acid-sequence peptide reacted with 9 HVR1 pro-
eins including 12-22 among the 25 HVR1 proteins of
enotype 1b. The C-terminal 13-amino-acids sequences
ere compared between the group of HVR1 proteins
eactive with the immune sera and that of those nonre-
ctive. There was no difference between the two groups
n the number of amino acids different from C-terminal
3-amino-acids sequence of HVR1 protein 12-22. The vVR1 proteins reactive with the rabbit immune sera were
eactive with significantly larger number of patients’ sera
33.7 6 14.2) than those nonreactive with rabbit immune
era (18.3 6 8.4) (P , 0.005).
The rabbit immune sera reacted with 3 of 12 HVR1
roteins of genotype 2a. All 3 HVR1 proteins reactive
ith the immune sera had similar sequences (from po-
ition 399 to position 406) to HVR1 protein 12-22 (Fig. 3).
VR1 proteins 21-26 and 17-7 also had similar se-
uences to HVR1 protein 12-22 but did not react with the
mmune sera.
DISCUSSION
The present study demonstrated that the broad reac-
ivity of HVR1 proteins with patients’ sera significantly
orrelated with their similarity to the consensus se-
uence. HCV is present as quasispecies where a large
umber of HCV variants coexist simultaneously or exist
n time course in a single patient (Hijikata et al., 1991;
gata et al., 1991; Weiner et al., 1991; Martell et al., 1992;
igashi et al., 1992). Because the consensus sequence
onsists of the commonest residues at each position,
FIG. 1. The amino acid sequence of 25 HVR1 proteins and the
onsensus sequence defined by Puntoriero et al. (1998). Amino acid
esidues are indicated by standard single-letter codes. Dashes indicate
esidues identical to the residues at the uppermost position of the
onsensus sequence. The residues not identical to those of consensus
equence at the position were underlined. The number of patients’ sera
eactive with the individual HVR1 protein is in parentheses.ariants similar to the consensus sequence are probably
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155BROAD IMMUNO-REACTIVITY OF HVR1 PROTEINS OF HCVore frequently generated and challenge the immune
ystem than those dissimilar to the consensus se-
uence. Thus our observation that HVR1 proteins similar
o the consensus sequence were more frequently reac-
ive with patients’ sera than HVR1 proteins dissimilar to
he consensus appears reasonable.
The consensus sequence adopted in the present
tudy was reported by Puntoriero et al. (1998). Several
ther reports describing the most common amino acids
t each position of HVR1 (Sekiya et al., 1994; Nakamoto
t al., 1996; McAllister et al., 1998) showed a complete
oncordance with the consensus sequence reported by
untoriero et al. The presence of this valid consensus
equence suggests that the variants similar to the con-
ensus sequence have some advantages in the persis-
ence of HCV infection and that HVR1 has some function
ssential to maintain infection. Anti-HVR1 antibodies
ave been reported to inhibit E2 protein or HCV to bind
o target cells (Zibert et al., 1995; Rosa et al., 1996). These
tudies indicate that HVR1 may have a role in the binding
f viruses to cellular receptors. Further work is needed to
lucidate the virological functions of HVR1.
The present study demonstrated that a portion of pa-
ients’ sera contained no or little cross-reactive anti-
T
Reactivity of 25 HVR1 Fusion Proteins an
HVR1 fusion
protein No. of reactive sera OD of reactivity with patien
12-22 60 0.99 6 0.80 (0;2.54
13-1 42 0.55 6 0.72 (0;2.60
14-1 40 0.63 6 0.84 (0;3.01
10-6 40 0.52 6 0.68 (0;2.38
15-16 35 0.47 6 0.72 (0;2.42
13-11 35 0.41 6 0.58 (0;2.35
10-3 29 0.33 6 0.51 (0;1.66
3-6 28 0.35 6 0.62 (0;2.43
7-4 27 0.29 6 0.48 (0;1.90
3-1 27 0.34 6 0.58 (0;1.94
11-2 25 0.25 6 0.48 (0;2.01
1-22 24 0.31 6 0.60 (0;2.19
10-4 22 0.26 6 0.53 (0;2.36
2-36 19 0.22 6 0.48 (0;2.00
2-3 18 0.18 6 0.39 (0;1.52
3-2 17 0.19 6 0.47 (0;2.49
6-21 15 0.16 6 0.39 (0;2.00
8-22 15 0.18 6 0.46 (0;2.27
9-21 15 0.17 6 0.45 (0;2.69
4-37 14 0.11 6 0.27 (0;1.36
7-1 14 0.16 6 0.44 (0;2.51
11-1 14 0.15 6 0.40 (0;2.00
5-1 9 0.09 6 0.30 (0;1.73
8-21 9 0.07 6 0.23 (0;1.31
4-22 2 0.01 6 0.09 (0;0.73
Note. The consensus sequence defined by Puntoriero et al. (1998).
a The peptide with C-terminal 13-amino-acids sequence of HVR1
mmunogen.VR1 antibodies. Ten sera had no detectable antibody, pnd 20 sera had low reactivity with OD ,1.0 even with
he most reactive HVR1 protein. Thus these patients may
ave no neutralizing antibodies or their antibodies may
e insufficient because of low titer. We have already
eported the deficiency of humoral immune response to
heir own HVR1 variants in some HCV-infected patients
Yoshioka et al., 1996, 1997). Limited humoral immunity in
CV infection such as IgG1 restriction and low titer was
lso shown recently (Chen et al., 1999). Further studies
re necessary to elucidate whether the absence or scar-
ity of anti-HVR1 antibodies measured by enzyme-linked
mmunoassay or Western blot correlates with clinical
ourses of HCV infection.
In early studies, neutralizing activity of anti-HVR1 an-
ibodies has been reported to be isolate-specific (Farci et
l., 1996; Shimizu et al., 1996). However, recently murine
nti-HVR1 antibodies appear to cross-reactively capture
CV (Esumi et al., 1998). The cross-reactive anti-HVR1
ntibodies may possess efficient neutralizing activity
hen their titers are sufficiently high. In this case, it may
e possible to use HVR1 proteins in a HCV vaccine if
hey induce reasonably high titer of cross-reactive anti-
VR1 antibodies.
We reasoned that the most broadly reactive HVR1
r Similarity to the Consensus Sequence
a
No. of amino acid residues identical
to the consensus sequence
OD of reactivity with
rabbit immune seraa
26 2.12
24 2.13
26 1.92
22 0.82
22 1.85
26 0
21 0.71
22 0
25 1.83
25 0
22 0
26 0
22 0
24 0
22 0
22 0
24 1.24
22 0
20 1.92
20 0
22 0
23 0
20 0
25 0
18 0
are means 6 SD; ranges are in parentheses.
n 12-22 (NH2-CSFTSLFTPGPSQK) was injected into rabbits as anABLE 1
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156 WATANABE ET AL.ause the most broadly reactive HVR1 protein, 12-22,
as disclosed to be also reactive with 53% of sera of
atients infected by genotype 2a, the immune sera were
xpected to be reactive with HVR1 protein of genotype
a. As we expected, rabbit immune sera against C-
erminal 13-amino-acids peptide of HVR1 12–22 reacted
ith 9 of 25 HVR1 proteins with genotype 1b and even
ith 3 of 12 proteins of genotype 2a. Puntoriero et al.
1998) also reported that mimotopes of HVR1 broadly
eactive with patients’ sera induced antibodies cross-
eactive with a large number of viral variants. Therefore
combination of several HVR1 proteins should be able
o induce antibodies reactive with all the HVR1 variants
nd can be considered as a candidate prophylactic vac-
ine against HCV.
The present study demonstrates that HVR1 proteins
imilar to the consensus were more frequently reactive
ith patients’ sera than HVR1 proteins dissimilar to the
onsensus. We suggest the possibility that a combina-
ion of broadly reactive proteins could serve in a prophy-
actic vaccine against HCV.
MATERIALS AND METHODS
atients
The sera of 81 patients with chronic hepatitis C were
ssayed for the reactivity with HVR1 proteins. HCV ge-
otype was determined by Okamoto’s method (Okamoto
t al., 1992) and was 1b for all the patients according to
FIG. 2. Correlation between the broad reactivity of individual HVR1
roteins with patients’ sera and their similarity to the consensus se-
uence defined by Puntoriero et al. (1998). The similarity to the con-
ensus sequence was expressed as the number of amino acid resi-
ues identical to the consensus sequence. The number of amino acid
esidues identical to the consensus sequence significantly correlated
ith the number of sera reactive with each HVR1 protein (r 5 0.561, P ,
.005).immonds’ classification (Simmonds et al., 1993). 1VR1 fusion proteins
25 HVR1 clones of genotype 1b and 12 clones of
enotype 2a (1–3 clones from each patient) were se-
ected from clones previously obtained from 20 patients
ho were not included in this study and the HVR1 fusion
roteins were purified from Escherichia coli transfected
ith these clones (Fig. 1). The production of these HVR1
roteins and reactivity with corresponding sera were
escribed in a previous report (Yoshioka et al., 1997).
riefly, the cDNA fragments containing HVR1 (aa 384–
10) were amplified by polymerase chain reaction (PCR)
sing the primers for genotype 1b (sense primer: nt
117–1147; 59-ATTGGAATTCTGCTCTTTGCCGGCGTTGA-
GG-39, antisense primer: nt 1225–1254; 59-GCCAGA-
CTCTTTATAAGCTGGATTTTCTG-39) or the primers for
enotype 2a (sense primer: nt 1120–1148; 59-ATCCGAAT-
CTGGCCGCTGGGGTGGACGC-39, antisense primer: nt
225–1254; 59-GCCAGAGCTCTTAATGAGCTGGATGTTC-
G-39). The PCR products were ligated into the SacI and
coRI sites of the expression vector pGEX-2T (Pharma-
ia Biotech, Uppsala, Sweden) where HVR1s were to be
xpressed as fusion proteins with glutathione-S-trans-
erase (GST). We added SacI site to the original restric-
ion enzyme sites of pGEX-2T. The vectors were trans-
ected to E. coli DH5a, and GST fusion proteins were
xpressed by induction with 0.4 mM isopropyl-b-D-thio-
alactopyranoside and purified by glutathione agarose
eads (Sigma Chemical Co., St. Louis, MO).
The nucleotide sequence data reported in this paper
an be accessed in the DDBJ, EMBL and GenBank nu-
leotide sequence databases with the following acces-
ion numbers: AB003915, AB003916, AB003917,
B003918, and AB003919.
FIG. 3. C-terminal 13-amino-acids sequences of the 12 HVR1 pro-
eins of genotype 2a. Amino acid residues are indicated by standard
ingle-letter codes. Dashes indicate residues identical to HVR1 protein
2-22. In parentheses is OD of reactivity of the individual HVR1 protein
ith the rabbit immune sera against the peptide bearing C-terminal3-amino-acids sequence of HVR1 protein 12-22.
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157BROAD IMMUNO-REACTIVITY OF HVR1 PROTEINS OF HCVestern blot analysis
The purified GST fusion proteins were run on 12%
olyacrylamide gel with sodium dodecyl sulfate by
aemmli’s method (Laemmli, 1970). Fusion proteins (0.5
g) were applied to each lane of gels. The proteins were
ransferred from the gel onto Immobilon transfer mem-
rane (Nippon Millipore Co., Tokyo, Japan) by electro-
lotting. The filter was blocked with 2% skimmed milk
nd was reacted with patients’ sera (1:40 dilution) at
oom temperature for 2 h followed by incubation with
oat anti-human IgG gamma chain conjugated with
orseradish peroxidase (Tago, Inc., Burlingame, CA). The
ntibody binding was visualized by the reaction with
iamino benzidine in the presence of 0.03% H2O2, and
as quantified by GT-6500ART image scanner (Seiko-
pson Co., Suwa, Japan) and 1D Analysis program (Ad-
anced American Biotechnology Inc., Fullerton, CA). The
eactivity of antibody was expressed as optical density
OD).
mmunization of rabbits with the peptide of the most
roadly reactive HVR1
The immunizing peptide was prepared by Sawady
echnology (Tokyo, Japan) and conjugated with keyhole
impet hemocyanin. The peptide had the 13-amino-acids
equence of C-terminal of HVR1 12–22 (NH2-CSFTSLFT-
GPSQK); cys was added to C-terminal end for the con-
ugation onto keyhole limpet hemocyanin. Rabbits were
mmunized by intracutaneous injection of 500 mg of the
eptide with complete Freund’s adjuvant at Day 0 and
ith Incomplete Freund’s adjuvant at Days 14 and 28 and
led at Day 42. The immunized rabbit sera were tested
or the reactivity with 25 HVR1 proteins of genotype 1b
nd 12 HVR1 proteins of genotype 2a by Western blot.
tatistical analysis
The results were analyzed by the unpaired Student’s t
est or by linear regression analysis.
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